The trajectory of copyright's flagship drug presents a nuanced case for investors in the pharmaceutical sector. While initially a blockbuster success, generating huge profits, the patent lapse and the subsequent https://pharma365452.vidublog.com/40427920/sildenafil-and-pharma-a-risky-bet